CSIR-IMTECH is organizing a one day 'Dr Paul Janssen TB Symposium' on 17th August 2017. The aim of this symposium is to brainstorm on issues related to TB drug development & public policy. This symposium endeavours to reinforce the vision laid out by late Dr. Paul Janssen who dedicated his life for creating medicines that benefitted millions of patients across the globe.
This symposium will be graced by Paul Stoffels, M.D., Chief Scientific Officer of healthcare giant Johnson & Johnson and will also include key government policy makers including leaders from Ministry of Science and Technology to discuss the future research agenda around TB in India
Dr. Paul Janssen was the world's most prolific discoverer of new medicines. He changed the course of drug discovery and development in the 20th century. The loss of his four year old sister due to TB meningitis drove him to pursue a career in medicine. Dr. Paul was the holder of more than 100 patents and has 80 medicines to his credit. One of his last dreams, to find a medicine to treat TB was realized by Janssen with the first new treatment for tuberculosis in more than 40 years.
About Paul Stoffels, M.D.
Paul Stoffels, M.D. studied Medicine in Belgium and began his career as a physician in Africa, as part of the Janssen Research Foundation (JRF) under the mentorship of Dr. Paul Janssen, focusing on HIV and tropical diseases research. During this time, Paul witnessed first-hand the devastation being caused by a new and unknown disease - HIV, more commonly known as AIDS.
He founded a company named Tibotec to focus on HIV treatment and Virco, focused on diagnostics. As a result of this team's work, three leading products for the treatment of HIV were eventually developed - PREZISTA, INTELENCE and EDURANT. Paul Stoffels, M.D. joined Johnson & Johnson in 2002 and is currently the Chief Scientific Officer of Johnson & Johnson.
Global public health is a life-long passion for Paul Stoffels, M.D. . Under his leadership, Johnson & Johnson brought forward Bedaquiline - the first new drug for MDR-TB in more than four decades and launched a new Global Public Health strategy that leverages the Company's resources to improve health outcomes among vulnerable populations. He was instrumental in building the relationship between UNAIDS/WHO and the pharmaceutical industry with regard to the provision of HIV drugs in Africa. More recently, Paul Stoffels, M.D. has become a sought-after partner and thought leader on issues of anti-microbial resistance, pandemic preparedness, and access to medicines.